Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Commentary

The clinical significance of tumor infiltrating lymphoctyes in breast cancer: does subtype matter?

Authors: Jonathan Krell, Adam E Frampton, Justin Stebbing

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Tumor infiltrating lymphocytes (TILs) are commonly detected in breast tumors but their bearing on disease outcome is uncertain. The importance of TILs appears to be subtype-specific and varies depending on the histologic characteristics of the tumor. As our understanding of tumorigenesis is increasing the relevance of immunobiology will become apparent.
Literature
1.
Caprioli RM: Deciphering protein molecular signatures in cancer tissues to aid in diagnosis, prognosis, and therapy. Cancer Res. 2005, 65 (23): 10642-10645. 10.1158/0008-5472.CAN-04-3581.CrossRefPubMed
2.
Calin GA, Croce CM: MicroRNA signatures in human cancers. Nature reviews Cancer. 2006, 6 (11): 857-866. 10.1038/nrc1997.CrossRefPubMed
3.
Pandolfi F, Cianci R, Pagliari D, Casciano F, Bagala C, Astone A, Landolfi R, Barone C: The Immune Response to Tumors as a Tool toward Immunotherapy. Clinical & developmental immunology. 2011, 2011: 894704-CrossRef
4.
Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR: Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011, 29 (15): 1949-1955. 10.1200/JCO.2010.30.5037.CrossRefPubMed
5.
Trzonkowski P, Szmit E, Mysliwska J, Dobyszuk A, Mysliwski A: CD4 + CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol. 2004, 112 (3): 258-267. 10.1016/j.clim.2004.04.003.CrossRefPubMed
6.
Murakami M, Sakamoto A, Bender J, Kappler J, Marrack P: CD25 + CD4+ T cells contribute to the control of memory CD8+ T cells. Proc Natl Acad Sci USA. 2002, 99 (13): 8832-8837. 10.1073/pnas.132254399.CrossRefPubMedPubMedCentral
7.
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006, 313 (5795): 1960-1964. 10.1126/science.1129139.CrossRefPubMed
8.
Oble DA, Loewe R, Yu P, Mihm MC: Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer immunity: a journal of the Academy of Cancer Immunology. 2009, 9: 3-PubMed
9.
Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B: Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003, 9 (2): 606-612.PubMed
10.
Nedergaard BS, Ladekarl M, Thomsen HF, Nyengaard JR, Nielsen K: Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer. Br J Cancer. 2007, 97 (8): 1135-1138. 10.1038/sj.bjc.6604001.CrossRefPubMedPubMedCentral
11.
Matkowski R, Gisterek I, Halon A, Lacko A, Szewczyk K, Staszek U, Pudelko M, Szynglarewicz B, Szelachowska J, Zolnierek A, et al: The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. Anticancer research. 2009, 29 (7): 2445-2451.PubMed
12.
Rakha EA, Aleskandarany M, El-Sayed ME, Blamey RW, Elston CW, Ellis IO, Lee AH: The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer. 2009, 45 (10): 1780-1787. 10.1016/j.ejca.2009.02.014.CrossRefPubMed
13.
Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Menard S, Tagliabue E, Balsari A: FOXP3 expression and overall survival in breast cancer. J Clin Oncol. 2009, 27 (11): 1746-1752. 10.1200/JCO.2008.17.9036.CrossRefPubMed
14.
Horlock C, Stott B, Dyson PJ, Morishita M, Coombes RC, Savage P, Stebbing J: The effects of trastuzumab on the CD4 + CD25 + FoxP3+ and CD4 + IL17A + T-cell axis in patients with breast cancer. Br J Cancer. 2009, 100 (7): 1061-1067. 10.1038/sj.bjc.6604963.CrossRefPubMedPubMedCentral
15.
Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010, 28 (1): 105-113. 10.1200/JCO.2009.23.7370.CrossRefPubMed
16.
Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, et al: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988, 319 (25): 1676-1680. 10.1056/NEJM198812223192527.CrossRefPubMed
17.
Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, Steinberg GD, Belldegrun AS: Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol. 1999, 17 (8): 2521-2529.PubMed
Metadata
Title
The clinical significance of tumor infiltrating lymphoctyes in breast cancer: does subtype matter?
Authors
Jonathan Krell
Adam E Frampton
Justin Stebbing
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-135

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue

Research article

Effects of partner proteins on BCA2 RING ligase activity

Research article

Complement activation in astrocytomas: deposition of C4d and patient outcome

Research article

Association of estrogen receptor betavariants and serum levels of estradiol with risk of colorectal cancer: a case control study

Research article

Is there a role of whole-body bone scan in patients with esophageal squamous cell carcinoma

Research article

Development of a gene therapy strategy to target hepatocellular carcinoma based inhibition of protein phosphatase 2A using the α-fetoprotein promoter enhancer and pgk promoter: an in vitro and in vivo study

Research article

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits